Abstract
Background There is majority support in parliament and across the United Kingdom (UK) to implement a ‘smokefree generation’ policy which would increase the legal age of sale of tobacco from 18 by one year each year from 2027 onwards, such that people born on or after 1 January 2009 could never legally be sold tobacco. To explore the potential impact this policy could have, we estimated the number of young adults (18–25y) currently taking up smoking each year by area across the UK.
Methods Using data from the Office for National Statistics (ONS), Annual Population Survey (APS), and Smoking Toolkit Study (STS), we estimated the total number of 18–25-year-olds in the UK taking up smoking each year, based on national estimates of population size (ONS) and the proportion who reported ever having been a regular smoker (STS). We used local data on adult smoking rates (APS) to apportion the national estimated number of young adults taking up smoking to specific areas.
Results Around 127,500 18–25-year-olds in the UK start smoking regularly each year (349 each day); 105,700 each year (290 each day) in England, 11,500 (32) in Scotland, 6,500 (18) in Wales, and 3,800 (10) in Northern Ireland. Estimates of uptake varied across localities: for example, North East Lincolnshire had the highest proportion of young adults taking up smoking each year (3.96%) and Wokingham had the lowest (0.85%).
Conclusions Despite reductions in smoking prevalence over recent decades, hundreds of young adults in the UK start smoking every day. Data on rates of uptake among individual local authorities can be used to focus attention locally prior to the introduction of new age of sale laws.
Competing Interest Statement
JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Funding Statement
This work was supported by Cancer Research UK (PRCRPG-Nov21\100002).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of UCL gave ethical approval for this work (ID 0498/001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available on the Open Science Framework (https://osf.io/nu2rp/)
